Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Waters (WAT) strengthens the product portfolio by introducing TRIOS AutoPilot software for the thermal analyzer product line.

Waters (WAT) Boosts Thermal Analysis With Latest Software

NEW CASTLE, Del.--(BUSINESS WIRE)---- $WAT #thermalanalysis--TRIOS AutoPilot software is now available for the TA Instruments thermal analysis product line.

TA Instruments Helps Laboratories Automate Thermal Analysis Workflows with New TRIOS AutoPilot Software

MILFORD, Mass. & SINGAPORE--(BUSINESS WIRE)---- $WAT #bioinformatics--Waters expands collaboration with Singapore's Bioprocessing Technology Institute, A*STAR to accelerate bioprocessing and bioinformatics research.

Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore's Bioprocessing Technology Institute

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corp. will appoint Wei Jiang, EVP and President of APAC and China at Bayer Pharmaceuticals, to the Waters Board of Directors.

Waters Corporation Appoints Wei Jiang to Board of Directors

Waters (WAT) expands the product portfolio by introducing Arc Premier System for chromatographic separations.

Waters (WAT) Expands Reach to Scientists Via Latest Launch

MILFORD, Mass.--(BUSINESS WIRE)-- #UHPLC--The Waters Arc Premier System with MaxPeak HPS technology is optimized for chromatographic separations on 2.5 – 3.5 micron MaxPeak Premier Columns.

Waters Arc Premier System Delivers Increased Precision and Certainty in Chromatographic Results

MILFORD, Mass.--(BUSINESS WIRE)-- #imagingmassspec--Waters Sets New Standard in High Resolution Mass Spectrometry with the Introduction of the SELECT SERIES Multi Reflecting Time-of-Flight Platform

Waters Sets New Standard in High Resolution Mass Spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight Platform

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Why Is Waters (WAT) Up 2.4% Since Last Earnings Report?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results. “For biomedical and clinical research laboratories that are involved in fighting the pandemic, this kit offers a

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation Celebrates the Life and Legacy of its Founder, Jim Waters

Waters Corporation Celebrates the Life and Legacy of its Founder, Jim Waters

FRAMINGHAM, Mass. & MILFORD, Mass.--(BUSINESS WIRE)--SCIEX and Waters Corporation collaborate to deliver fully configured and interoperable LC-MS systems

SCIEX and Waters Corporation Collaborate to Deliver Fully Configured and Interoperable LC-MS Systems

Waters' (WAT) first-quarter results reflect gains from strong momentum across Asia, the Americas and Europe, and robust performance in the pharmaceutical and industrial markets.

Waters (WAT) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

Waters Corporation's (WAT) CEO Udit Batra on Q1 2021 Results - Earnings Call Transcript

Waters (WAT) delivered earnings and revenue surprises of 45.86% and 16.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Q1 Earnings and Revenues Top Estimates

Waters Corp (NYSE: WAT) reported first-quarter FY21 net sales growth of 31% year-on-year to $608.5 million, beating analyst consensus of $525.29 million. Net sales from Waters and TA segments rose 31% to $541.9 million and $66.7 million, respectively.

Waters Crushes Q1 Earnings, Q2 Guidance Exceed Wall Street's Consensus

Shares of Waters (NYSE:WAT) rose 1.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 99.13% over the past year to $2.29, which beat the estimate of $1.57.

Recap: Waters Q1 Earnings

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced first quarter 2021 sales of $609 million, a 31% increase as reported, compared to sales of $465 million for the first quarter of 2020. Foreign currency translation benefited sales growth by approximately 4% for the quarter. On a GAAP basis, diluted earnings per share (EPS) for the first quarter of 2021 increased to $2.37, compared to $0.86 for the first quarter of 2020. On a non-GAAP basis, EPS increased to $2.29, c

Waters Corporation (NYSE: WAT) Reports First Quarter 2021 Financial Results

Ecopetrol

Fair Isaac

Twenty-First Century Fox

Sun Life Financial

Six corporate bigwigs with a favorable Zacks Rank are set to beat the earnings estimates this week. These are: EC, CDW, FOXA, SLF, FICO and WAT.

Top 6 Corporate Bigwigs Poised to Beat on Earnings This Week

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12th, 2021 at 2:00PM Eastern Standard Time. Interested investors can access the live webcast of the presentation by logging on to Waters Corporation's website www.waters.com in the investor relations' section and clicking on “Bank of America Securities

Waters Corporation Presentation at the Bank of America Securities 2021 Virtual Health Care Conference to Be Audio Webcast Live

Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Waters (WAT) Reports Next Week: Wall Street Expects Earnings Growth

Waters' (WAT) first-quarter 2021 results are likely to reflect strength across liquid chromatography instruments and mass spectrometers.

Waters (WAT) to Report Q1 Earnings: A Beat in the Cards?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) continues its transformation program with the announcement of several planned leadership appointments and executive retirements. Amol Chaubal will assume the role of Senior Vice President and Chief Financial Officer, effective May 12, 2021. Mr. Chaubal joins Waters from Quanterix Corporation, a publicly traded life sciences company, where he served as Chief Financial Officer since April 2019, helping to oversee a period of strong s

Waters Corporation Continues Transformation with Planned Leadership Transitions

Waters (WAT) collaborates with Genovis for developing automated biotherapeutic characterization workflows.

Waters (WAT) Teams Up With Genovis, Boosts Biopharma Reach

Adobe

Applied Materials

Generac Holdings

Alphabet

Here we pick five tech stocks - Applied Materials (AMAT), Generac (GNRC), Waters (WAT), Alphabet (GOOGL) and Adobe (ADBE) - that are well-poised to grow in the near term on expectation of stronger economic recovery.

5 Top Growth Tech Stocks to Buy for Solid Returns in Q2

MILFORD, Mass. & LUND, Sweden--(BUSINESS WIRE)-- #antidrugconjugates--Waters Corporation and Genovis AB are collaborating to develop and market complete routine biopharmaceutical characterization workflows.

News for Waters Stock (WAT)